CompanyGraph
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- ScaleMarket cap is $3.24B, above the global median of $1.15B
- FinancialsAltman Z-Score 6.35: safe zone
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
308.85BINR3.24B · vs all stocks (USD)
Trailing P/E
144.98xRevenue (TTM)
33.73BINR354.27M · vs all stocks (USD)
Profit Margin
6.31%Beta
0.9340xvs all stocks
52-Week Change
9.68%vs all stocks
Market Capitalization
308.85BINR3.24B · vs all stocks (USD)
Enterprise Value
327.03BINR3.43B · vs all stocks (USD)
Trailing P/E
144.98xPEG Ratio
0.1416xPrice to Sales (TTM)
9.16xPrice to Book (MRQ)
6.24xEnterprise to Revenue
9.70xEnterprise to EBITDA
51.91xGross Margin
67.05%Profit Margin
6.31%Operating Margin
14.82%Return on Assets (TTM)
3.01%Return on Equity (TTM)
4.00%Revenue (TTM)
33.73BINR354.27M · vs all stocks (USD)
Revenue per Share (TTM)
207.76INRUpdated Jul 20, 2026Quarterly Revenue Growth
26.00%Gross Profit (TTM)
22.41BINR235.37M · vs all stocks (USD)
EBITDA (TTM)
7.63BINR80.14M · vs all stocks (USD)
Net Income (TTM)
2.13BINR22.37M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
33.84%Operating Cash Flow (TTM)
3.90BINR40.96M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-3.99BINR-41.93M · vs all stocks (USD)
Payout Ratio
0.00%Minority Interest (Equity)
3.41BINRFY2026 · Mar 31, 2026Revenue
33.73BINRFY2026 · Mar 31, 2026Cost of Goods Sold
11.32BINRFY2026 · Mar 31, 2026Gross Profit
22.41BINRFY2026 · Mar 31, 2026Operating Income
4.03BINR42.33M · vs all stocks (USD)
Pre-tax Income
2.38BINRFY2026 · Mar 31, 2026Income Tax Expense
390.00MINRFY2026 · Mar 31, 2026Net Income
1.99BINRFY2026 · Mar 31, 2026EBIT
4.51BINRFY2026 · Mar 31, 2026EBITDA (Income Statement)
7.63BINRFY2026 · Mar 31, 2026Other Operating Expenses
8.86BINRFY2026 · Mar 31, 2026Non-operating Interest Expense
2.13BINRFY2026 · Mar 31, 2026Minority Interests (P&L)
140.00MINRFY2026 · Mar 31, 2026Preferred Stock Dividends
0.00INRFY2026 · Mar 31, 2026Operating Cash Flow
2.71BINRFY2026 · Mar 31, 2026Free Cash Flow
1.85BINRFY2026 · Mar 31, 2026Cash & Cash Equivalents (End of Period)
2.17BINRFY2026 · Mar 31, 2026Starting Profit (CF Statement)
2.38BINRFY2026 · Mar 31, 2026Stock-based Compensation
40.00MINRFY2026 · Mar 31, 2026Other Non-cash Items
3.11BINRFY2026 · Mar 31, 2026Change in Accounts Receivable (CF)
500.00MINRFY2026 · Mar 31, 2026Change in Other Assets/Liabilities
-3.32BINRFY2026 · Mar 31, 2026Capital Expenditures
-860.00MINRFY2026 · Mar 31, 2026Net Intangibles (CF)
-2.28BINRFY2026 · Mar 31, 2026Sale of Investments
390.00MINRFY2026 · Mar 31, 2026Other Investing Activity
290.00MINRFY2026 · Mar 31, 2026Net Investing Cash Flow
-180.00MINRFY2026 · Mar 31, 2026Long-term Debt Issuance
7.37BINRFY2026 · Mar 31, 2026Long-term Debt Payments
-5.25BINRFY2026 · Mar 31, 2026Net Short-term Debt Issuance
-700.00MINRFY2026 · Mar 31, 2026Net Financing Cash Flow
1.42BINRFY2026 · Mar 31, 2026Shares Outstanding
162.49MSharesUpdated Jul 20, 2026Float Shares
76.38MSharesUpdated Jul 20, 2026% Held by Insiders
51.02%vs all stocks
% Held by Institutions
14.79%vs all stocks
Total Cash (MRQ)
7.13BINR74.89M · vs all stocks (USD)
Total Cash per Share (MRQ)
43.94INRUpdated Jul 20, 2026Total Debt (MRQ)
22.33BINR234.53M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.4228xCurrent Ratio (MRQ)
1.66xBook Value per Share (MRQ)
304.44INRUpdated Jul 20, 2026Total Assets
86.15BINR904.83M · vs all stocks (USD)
Total Current Assets
26.97BINRFY2026 · Mar 31, 2026Total Liabilities
33.34BINRFY2026 · Mar 31, 2026Total Non-current Assets
59.18BINRFY2026 · Mar 31, 2026Total Non-current Liabilities
17.12BINRFY2026 · Mar 31, 2026Total Current Liabilities
16.22BINRFY2026 · Mar 31, 2026Cash
2.17BINRFY2026 · Mar 31, 2026Cash & Cash Equivalents
2.17BINRFY2026 · Mar 31, 2026Other Short-term Investments
4.12BINRFY2026 · Mar 31, 2026Accounts Receivable
5.88BINRFY2026 · Mar 31, 2026Inventory
8.87BINRFY2026 · Mar 31, 2026Accounts Payable
5.63BINRFY2026 · Mar 31, 2026Short-term Debt
6.77BINRFY2026 · Mar 31, 2026Other Current Liabilities
130.00MINRFY2026 · Mar 31, 2026Long-term Debt
15.56BINRFY2026 · Mar 31, 2026Other Non-current Liabilities
640.00MINRFY2026 · Mar 31, 2026Common Stock (Book)
810.00MINRFY2026 · Mar 31, 2026Retained Earnings
4.63BINRFY2026 · Mar 31, 2026Total Shareholders' Equity
52.81BINR554.66M · vs all stocks (USD)
52-Week Low
1.09KINRUpdated Jul 20, 202652-Week High
2.42KINRUpdated Jul 20, 202652-Week Change
9.68%vs all stocks
Beta
0.9340xvs all stocks
50-Day MA
1.85KINRUpdated Jul 20, 2026200-Day MA
1.48KINRUpdated Jul 20, 2026Avg 10-Day Volume
634.20KSharesUpdated Jul 20, 2026Avg 30-Day Volume
1.13MSharesUpdated Jul 20, 2026Diluted EPS (TTM)
13.11INRUpdated Jul 20, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.67Profit Margin: 0.06
Financial Health
Altman Z-Score 6.35: safe zoneNotable
Altman Z-Score: 6.35
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Scale
Market cap is $3.24B, above the global median of $1.15BNotable
Market cap (USD): 3,243,839,550.249Global Median: 1,146,734,693.424
Companies that share the same coordination system — how they create, deliver, or capture value.
Integer Holdings Corporation
Tier 1ProductionApproval-Gated PipelineRule
Betta Pharmaceuticals Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
ABL Bio Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Jilin Aodong Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Lepu Medical Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Hybio Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
BioArctic AB
Tier 1ProductionApproval-Gated PipelineRuleRisk
Shanghai Haoyuan Chemexpress Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Harbin Pharmaceutical Group Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Hebei Changshan Biochemical Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow